OncoMatch/Clinical Trials/NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Is NCT07189871 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies 177Lu-BetaBart for castration-resistant prostate cancer (crpc).
Treatment: 177Lu-BetaBart — A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Cancer type
Prostate Cancer
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: lu-177-psma radioligand therapy
Lab requirements
Blood counts
Platelet count ≥ 100 x 10^9/L; ANC ≥ 1.5 x 10^9/L; Hemoglobin ≥ 9 g/dL
Kidney function
eGFR ≥ 50 mL/min (CKD-EPI 2021)
Liver function
ALT or AST ≤ 3 x ULN (≤ 5 x ULN with liver metastases); total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN with Gilbert's syndrome)
Cardiac function
No unstable angina, MI within 6 months, NYHA Class II+ CHF, significant arrhythmia, LVEF < 50%, QTcF > 480 msec, or congenital long QT syndrome
Inadequate organ functions as reflected in laboratory parameters: eGFR < 50 mL/min; Platelet count < 100 x 10^9/L; ANC < 1.5 x 10^9/L; Hemoglobin < 9 g/dL; ALT or AST > 3 x ULN (> 5 x ULN with liver metastases); Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN; cardiac: see cardiovascular exclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dothan Hematology & Oncology · Dothan, Alabama
- BAMF Health · Grand Rapids, Michigan
- Nebraska Cancer Specialists · Omaha, Nebraska
- XCancer · Omaha, Nebraska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07189871 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior lu-177-psma radioligand therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages